强生公司近日宣布，其药物Inlexzo的永久性医疗保健通用程序编码系统（HCPCS）J码现已正式生效。该编码的落地将为医疗报销和药品管理提供标准化流程。
此次永久性J码的获批，标志着Inlexzo在医保支付体系中获得长期认可，有望提升该药物在临床使用中的可及性。医疗供应商现可通过该编码直接进行费用结算，简化了报销流程。
强生表示，这一进展体现了公司对优化医疗解决方案的持续承诺，也将为患者获得创新治疗方案提供更多便利。
强生公司近日宣布，其药物Inlexzo的永久性医疗保健通用程序编码系统（HCPCS）J码现已正式生效。该编码的落地将为医疗报销和药品管理提供标准化流程。
此次永久性J码的获批，标志着Inlexzo在医保支付体系中获得长期认可，有望提升该药物在临床使用中的可及性。医疗供应商现可通过该编码直接进行费用结算，简化了报销流程。
强生表示，这一进展体现了公司对优化医疗解决方案的持续承诺，也将为患者获得创新治疗方案提供更多便利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.